What is Krystexxa (pegloticase) used for?
Krystexxa is a brand of pegloticase, an IV medicine used to treat chronic gout in adults who have not responded to, or cannot use, other urate-lowering therapies. It’s prescribed to lower uric acid levels in the blood and help reduce gout flares and symptoms over time [1].
How does Krystexxa work?
Krystexxa contains pegloticase, an enzyme therapy. It breaks down uric acid in the bloodstream, lowering serum urate levels more directly than standard daily pills that reduce uric acid production or increase excretion [1].
How is it given and how quickly does it work?
Krystexxa is administered by IV infusion in a clinical setting. Dosing schedules follow the product’s prescribed regimen for gout management; treatment is usually based on how well uric acid levels are controlled and how the patient tolerates therapy [1].
What side effects do patients ask about?
Commonly reported risks with Krystexxa include infusion-related reactions. Patients may also experience gout flares as uric acid levels change during treatment. Your clinician typically monitors you closely during and after infusions [1].
Who should not use Krystexxa (or needs special caution)?
Eligibility depends on clinical factors such as prior treatment history and overall suitability for enzyme therapy. Because Krystexxa can cause infusion reactions and changes in urate levels, it requires medical supervision during infusions and monitoring as described in prescribing information [1].
Is Krystexxa still available, and what are alternatives?
Krystexxa is one option for difficult-to-treat gout when standard urate-lowering therapies are inadequate or not tolerated. Alternatives depend on the patient’s history and goals and can include other urate-lowering medicines or supportive flare-prevention strategies; the right choice depends on comorbidities and prior response [1].
What does the prescribing information say to check before starting?
Before treatment, clinicians review the diagnosis of gout, prior urate-lowering therapy use, and the plan for monitoring uric acid and managing infusion reactions. Detailed stopping and dose-modification guidance is contained in the full prescribing information [1].
Sources:
[1] https://www.krystexxa.com/about-krystexxa/